Good morning :)
Place Order
Add to Watchlist

Balaxi Pharmaceuticals Ltd

BALAXI

Balaxi Pharmaceuticals Ltd

BALAXI
Health CareHealth Care Equipment & Supplies
SmallcapWith a market cap of ₹413 cr, stock is ranked 1,933
High RiskStock is 3.82x as volatile as Nifty
76.061.67% (+1.25)
76.061.67% (+1.25)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareHealth Care Equipment & Supplies
SmallcapWith a market cap of ₹413 cr, stock is ranked 1,933
High RiskStock is 3.82x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareHealth Care Equipment & Supplies
SmallcapWith a market cap of ₹413 cr, stock is ranked 1,933
High RiskStock is 3.82x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
11.602.05
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.796.290.52%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The company is engaged in wholesale trading of pharmaceuticals products, food products and builders’ hardware products. The Company offers a range of food and biscuit products under the brand name YAP.

Investor Presentation

View older 

Nov 13, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 75.6%, vs industry avg of 16.09%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 1.27% to 8.13%

Loading...

Financial YearFY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue14.4946.22233.56284.36339.07241.92258.47
Raw Materialssubtract0.0032.83172.15195.60202.42128.68215.83
Power & Fuel Costsubtract0.000.000.000.350.280.04
Employee Costsubtract0.902.108.4712.4728.9528.04
Selling & Administrative Expensessubtract0.591.754.7417.5642.2936.02
Operating & Other expensessubtract10.550.703.302.595.0842.27
Depreciation/Amortizationsubtract0.000.010.300.511.752.102.10
Interest & Other Itemssubtract0.000.050.280.761.382.771.84
Taxes & Other Itemssubtract0.472.696.196.8610.964.403.10
EPS1.301.877.639.539.11-0.466.53
DPS0.000.000.000.100.000.000.00
Payout ratio0.000.000.000.010.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual Report Unavailable

Investor Presentation

Jun 24PDF
Feb 15PDF
Nov 2PDF
FY 2023

Annual Report Unavailable

Investor Presentation

May 29PDF
Feb 1PDF
Nov 5PDF
+2 more
FY 2024

Annual Report Unavailable

Investor Presentation

Aug 3PDF
FY 2025

Annual Report Pending

Investor Presentation

Nov 13PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareHealth Care Equipment & Supplies

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Balaxi Pharmaceuticals Ltd-172.092.05
Poly Medicure Ltd104.1718.300.11%
Tarsons Products Ltd49.863.470.50%
Borosil Scientific Ltd67.304.21

Price Comparison

Compare BALAXI with any stock or ETF
Compare BALAXI with any stock or ETF
BALAXI
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding65.99%0.00%0.02%16.48%17.50%

Mar 2024

Apr 2024

Jun 2024

Sep 2024

Shareholding History

SepDec '23MarAprJunSep18.57%18.57%17.08%17.08%16.88%16.48%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 1, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

0.50

Ex DateEx Date

Jul 1, 2022

News & Opinions
Earnings
Balaxi Pharmaceuticals consolidated net profit declines 68.19% in the September 2024 quarter

Net profit of Balaxi Pharmaceuticals declined 68.19% to Rs 4.59 crore in the quarter ended September 2024 as against Rs 14.43 crore during the previous quarter ended September 2023. Sales rose 41.41% to Rs 77.38 crore in the quarter ended September 2024 as against Rs 54.72 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales77.3854.72 41 OPM %13.6919.66 - PBDT6.0310.67 -43 PBT5.5610.01 -44 NP4.5914.43 -68 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals announces board meeting date

Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 November 2024Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Balaxi Pharmaceuticals reports consolidated net profit of Rs 6.48 crore in the June 2024 quarter

Net profit of Balaxi Pharmaceuticals reported to Rs 6.48 crore in the quarter ended June 2024 as against net loss of Rs 41.34 crore during the previous quarter ended June 2023. Sales declined 0.52% to Rs 65.62 crore in the quarter ended June 2024 as against Rs 65.96 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales65.6265.96 -1 OPM %15.3813.40 - PBDT7.877.54 4 PBT7.377.26 2 NP6.48-41.34 LP Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to conduct AGM

Balaxi Pharmaceuticals announced that the 81st Annual General Meeting(AGM) of the company will be held on 23 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Balaxi Pharmaceuticals to convene board meeting

Balaxi Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live